000			02235 a2200625 4500
005			20250517023057.0
264		0	_c20150629
008			201506s 0 0 eng d
022			_a1474-5488
024	7		_a10.1016/S1470-2045(15)70082-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aPui, Ching-Hon
245	0	0	_aClinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. _h[electronic resource]
260			_bThe Lancet. Oncology _cApr 2015
300			_a465-74 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdolescent
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aAsparaginase _xadministration & dosage
650	0	4	_aChild
650	0	4	_aChild, Preschool
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInfant
650	0	4	_aMale
650	0	4	_aMethotrexate _xadministration & dosage
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aNeoplasm, Residual _xchemically induced
650	0	4	_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aProspective Studies
650	0	4	_aRemission Induction
650	0	4	_aRisk Factors
650	0	4	_aUnited States
650	0	4	_aVincristine _xadministration & dosage
700	1		_aPei, Deqing
700	1		_aCoustan-Smith, Elaine
700	1		_aJeha, Sima
700	1		_aCheng, Cheng
700	1		_aBowman, W Paul
700	1		_aSandlund, John T
700	1		_aRibeiro, Raul C
700	1		_aRubnitz, Jeffrey E
700	1		_aInaba, Hiroto
700	1		_aBhojwani, Deepa
700	1		_aGruber, Tanja A
700	1		_aLeung, Wing H
700	1		_aDowning, James R
700	1		_aEvans, William E
700	1		_aRelling, Mary V
700	1		_aCampana, Dario
773	0		_tThe Lancet. Oncology _gvol. 16 _gno. 4 _gp. 465-74
856	4	0	_uhttps://doi.org/10.1016/S1470-2045(15)70082-3 _zAvailable from publisher's website
999			_c24734355 _d24734355